Headlines about Chimerix (NASDAQ:CMRX) have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Chimerix earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.8077384239663 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

CMRX has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Chimerix from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Cowen restated a “hold” rating and issued a $6.00 target price on shares of Chimerix in a report on Thursday, March 1st. BidaskClub upgraded shares of Chimerix from a “hold” rating to a “buy” rating in a report on Friday, March 9th. JPMorgan Chase & Co. downgraded shares of Chimerix from a “neutral” rating to an “underweight” rating in a research note on Wednesday, February 14th. Finally, HC Wainwright began coverage on shares of Chimerix in a research note on Friday, February 2nd. They set a “buy” rating and a $10.00 price objective for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. Chimerix presently has an average rating of “Hold” and an average price target of $7.06.

How to Become a New Pot Stock Millionaire

Chimerix (CMRX) traded down $0.01 during midday trading on Wednesday, hitting $5.87. 10,547 shares of the stock were exchanged, compared to its average volume of 236,643. Chimerix has a one year low of $4.17 and a one year high of $6.64. The firm has a market cap of $281.15, a P/E ratio of -3.88 and a beta of 1.34.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.07. Chimerix had a negative net margin of 1,579.53% and a negative return on equity of 29.22%. The company had revenue of $1.84 million during the quarter, compared to the consensus estimate of $0.83 million. equities analysts expect that Chimerix will post -1.78 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2018/03/14/chimerix-cmrx-getting-somewhat-favorable-press-coverage-report-shows.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Insider Buying and Selling by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.